iCAD, Inc. (ICAD)
NASDAQ: ICAD · Real-Time Price · USD
3.990
+0.070 (1.79%)
At close: May 16, 2025, 4:00 PM
3.890
-0.100 (-2.51%)
After-hours: May 16, 2025, 6:53 PM EDT
iCAD, Inc. Revenue
iCAD, Inc. had revenue of $4.87M in the quarter ending March 31, 2025, a decrease of -1.61%. This brings the company's revenue in the last twelve months to $19.53M, up 8.86% year-over-year. In the year 2024, iCAD, Inc. had annual revenue of $19.61M with 13.22% growth.
Revenue (ttm)
$19.53M
Revenue Growth
+8.86%
P/S Ratio
5.40
Revenue / Employee
$295,879
Employees
66
Market Cap
108.45M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 19.61M | 2.29M | 13.22% |
Dec 31, 2023 | 17.32M | -2.48M | -12.54% |
Dec 31, 2022 | 19.80M | -13.84M | -41.13% |
Dec 31, 2021 | 33.64M | 3.94M | 13.27% |
Dec 31, 2020 | 29.70M | -1.64M | -5.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ICAD News
- 4 days ago - iCAD Reports Financial Results for First Quarter Ended March 31, 2025 - GlobeNewsWire
- 4 weeks ago - ICAD INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iCAD, Inc. - ICAD - Business Wire
- 5 weeks ago - iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer - GlobeNewsWire
- 2 months ago - iCAD, Inc. (ICAD) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024 - GlobeNewsWire
- 2 months ago - iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America - GlobeNewsWire
- 2 months ago - Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025 - GlobeNewsWire
- 3 months ago - iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025 - GlobeNewsWire